JAMA Ophthalmology | Original Investigation

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
The STAIRWAY Phase 2 Randomized Clinical Trial

Arshad M. Khanani, MD, MA; Sunil S. Patel, MD, PhD; Philip J. Ferrone, MD; Aaron Osborne, MBBS; Jayashree Sahni, MBBS, MD; Susanna Grzeschik, PhD, RPh; Karen Basu, PhD; Jason S. Ehrlich, MD, PhD; Zdenka Haskova, MD, PhD; Pravin U. Dugel, MD

IMPORTANCE Faricimab neutralizes angiopoietin-2 and vascular endothelial growth factor A via both simultaneous and independent binding.

OBJECTIVE To evaluate extended dosing with faricimab, the first bispecific antibody designed for intraocular use, in patients with neovascular age-related macular degeneration.

DESIGN, SETTING, AND PARTICIPANTS This phase 2 randomized clinical trial was a 52-week multicenter, active comparator–controlled, parallel-group study. Study participants were enrolled in 25 sites in the US from January and March 2017 with treatment-naive choroidal neovascularization secondary to neovascular age-related macular degeneration and best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter score of 73 (approximate Snellen equivalent, 20/40) to 24 (approximate Snellen equivalent, 20/320). Analysis began January 2017 and ended March 2018.

INTERVENTIONS Participants were randomized 1:2:2 to receive intravitreal ranibizumab, 0.5 mg, every 4 weeks or faricimab, 6.0 mg, every 12 or 16 weeks. Participants in the faricimab arms initially received 4 monthly injections of faricimab. No rescue injections were allowed. Participants randomized to dosing every 16 weeks were assessed for disease activity at week 24 using prespecified criteria. Those with no active disease continued dosing every 16 weeks through trial end; participants with disease activity continued received dosing every 12 weeks.

MAIN OUTCOMES AND MEASURES Mean change in BCVA from baseline at week 40.

RESULTS Of 76 participants enrolled (mean [SD] age, 78.5 [8.5] years; age range, 56-94 years; 41 women [58%]; 69 white [97%]), 16 (21.0%) were randomized to ranibizumab every 4 weeks, 29 (38.2%) to faricimab every 12 weeks, and 31 (40.8%) to faricimab every 16 weeks. At week 24, 12 weeks after their last initiation injection, 65% (36 of 55) of all faricimab-treated participants had no disease activity. At week 40, adjusted mean BCVA gains from baseline (Early Treatment Diabetic Retinopathy Study letters) were +11.4 (80% CI, 7.8-15.0), +9.3 (80% CI, 6.4-12.3), and +12.5 (80% CI, 9.9-15.1) for the ranibizumab every 4 weeks, faricimab every 12 weeks, and faricimab every 16 weeks arms, respectively. Participants received a mean (SD) total of 12.9 (0.25), 6.7 (0.91), and 6.2 (093) injections, for the ranibizumab every 4 weeks, faricimab every 12 weeks, and faricimab every 16 weeks arms, respectively, through week 52. The secondary BCVA and anatomical imaging end points supported the primary end point and were comparable with ranibizumab every 4 weeks. No new or unexpected safety signals were identified.

CONCLUSIONS AND RELEVANCE At week 52, faricimab dosing every 16 weeks and every 12 weeks resulted in maintenance of initial vision and anatomic improvements comparable with monthly ranibizumab. These results suggest a role for simultaneous neutralization of angiopoietin-2 and vascular endothelial growth factor A in providing sustained efficacy through extended durability, warranting further investigation.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03038880

Invited Commentary

Video and Supplemental content

JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2020.2699
Published online July 30, 2020.

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Arshad M. Khanani, MD, MA, Sierra Eye Associates, 950 Ryland St, Reno, NV 89502 (arshad.khanani@gmail.com).

For more than a decade, intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has been first line in treating neovascular age-related macular degeneration (nAMD).[1-3] However, patients require frequent anti-VEGF injections to maintain visual outcomes.[3-5] Real-world outcome studies show that patients in clinical practice receive fewer injections than patients in randomized clinical trials, correlating with significant vision loss over time.[6-9] Frequent office visits and injections required to maintain vision gains place a significant treatment burden on patients, caregivers, health care professionals, and health care systems.[10-13]

Faricimab, the first bispecific antibody designed for intraocular use, both simultaneously and independently binds and neutralizes angiopoietin (Ang)-2 and VEGF-A with high specificity and potency.[14,15] The fragment crystallizable portion was specifically engineered to reduce systemic exposure and potential for inflammatory adverse events.[14-16] Ang-1/tyrosine kinase with immunoglobulinlike domains 2 signaling maintains stable vasculature and homeostasis; however, Ang-2 blocks Ang-1-mediated activation of tyrosine kinase with immunoglobulinlike domains 2, causing inflammation and vascular destabilization, including leakage and neovascularization.[17,18] Simultaneous Ang-2 and VEGF neutralization has additive benefits in preclinical models of choroidal neovascularization (CNV).[14,15,19] In patients with nAMD, the anti-inflammatory, antipermeability, antiangiogenic, and vascular stabilization effects of Ang-2 neutralization in addition to VEGF-A neutralization are hypothesized to contribute to a sustained effect on efficacy as a consequence of extended durability.

Faricimab was evaluated in the AVENUE (NCT02484690) and BOULEVARD (NCT02699450) phase 2 clinical trials for patients with nAMD and diabetic macular edema, respectively. AVENUE established that safety and efficacy of faricimab in nAMD at fixed dosing intervals every 4 weeks or every 8 weeks was comparable with monthly ranibizumab.[16] BOULEVARD demonstrated improved visual acuity using faricimab compared with ranibizumab in treatment-naive patients with diabetic macular edema and potential for sustained efficacy because patients treated with faricimab went longer before meeting disease reactivation criteria in the off-treatment observation period.[20] The present study, STAIRWAY, was designed to evaluate faricimab at dosing intervals every 16 weeks and every 12 weeks to address the unmet need for sustained efficacy through extended durability in nAMD. The 40- and 52-week outcomes from the STAIRWAY phase 2 trial are reported herein.

Key Points

Question How does extended dosing with faricimab compare with monthly ranibizumab in treating patients with neovascular age-related macular degeneration?

Findings In this phase 2 randomized clinical trial of faricimab in 76 patients, vision gains from baseline were +9.6, +10.1, and +11.4 letters for the monthly ranibizumab, faricimab every-12-weeks, and faricimab every-16-weeks arms, respectively, at week 52.

Meaning Through simultaneous neutralization of angiopoietin-2 and vascular endothelial growth factor A, faricimab maintains initial vision and anatomic improvements comparable with ranibizumab in neovascular age-related macular degeneration; the findings support pursuing extended interval dosing with faricimab in phase 3 trials as a potential alternative to more frequently dosed anti–vascular endothelial growth factor therapy.

Methods

STAIRWAY was a phase 2, multicenter, randomized, active comparator–controlled, participant- and outcome-assessor masked, parallel-group, 52-week clinical trial conducted at 25 sites in the United States between January and March 2017. All participants provided written informed consent. Accounting for the long investigation schedule, study participants received a stipend per visit completed, an extra stipend if they consented to optional aqueous humor sampling, and were reimbursed travel-related expenses. The study protocol and payment schedule were approved by institutional review boards (the full list of 25 sites is in Supplement 1) before study start. The study adhered to the tenets of the Declaration of Helsinki[21] and was conducted in accordance with Good Clinical Practice (GCP; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use E6)[22]; applicable US Food and Drug Administration regulations; applicable local, state, and federal laws; and the Health Insurance Portability and Accountability Act. The trial protocol is available in Supplement 1.

Study Population

Eligible participants were 50 years or younger with treatment-naive subfoveal or juxtafoveal CNV (with a subfoveal component related to the CNV activity) secondary to nAMD and best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 73 to 24 (20/40-20/320 Snellen equivalent). Only 1 eye was selected as the study eye; if the intended study eye was ineligible, rescreening was allowed to determine if the other eye would be eligible. Key study eye inclusion criteria were by fluorescein angiography (FA) (CNV lesion total size 6 disc areas or less, CNV component area at least 50% of total lesion size, and active CNV confirmed) and by spectral-domain optical coherence tomography (SD-OCT) (fluid presence by CNV exudation confirmed). Key ocular exclusion criteria were CNV owing to causes besides AMD and any prior or concomitant treatment for CNV, including but not limited to intravitreal treatment, laser photocoagulation, and verteporfin photodynamic therapy. Full inclusion and exclusion criteria are provided in eTable 1 in Supplement 2.

Randomization

Participants were randomized 1:2:2 to receive intravitreal ranibizumab, 0.5 mg, every 4 weeks; faricimab, 6.0 mg, every 12 weeks after initiation (4 total injections every 4 weeks from baseline to week 12); or faricimab, 6.0 mg, every 16 weeks after initiation (4 total injections every 4 weeks from baseline to week 12). Randomization was performed through an interactive voice and web response system (IxRS) and stratified for baseline BCVA (ETDRS letter score ≥55 vs ≤54).

Study Treatments and Assessments

Study treatment was administered up to week 48, with the final visit at week 52. The primary end point was at week 40. At week 24, disease activity was assessed using 6 per-protocol-defined criteria, based on changes in central subfield thickness (CST) and BCVA and any other disease activity per investigator opinion (eFigure 2 and eTable 2 in Supplement 2). Participants randomized to faricimab every 16 weeks who did not have disease activity at week 24 continued treatment every 16 weeks through study end, while participants with active disease at week 24 received treatment every 12 weeks through study end. Participants in the faricimab arm who received dosing every 16 weeks included both participants who, after the initial 4 monthly doses, continued dosing every 16 weeks through study end and those who received dosing every 12 weeks from week 24 owing to active disease detected at that time. Participants were not allowed to receive additional faricimab injections during the dosing periods for every 12 weeks or every 16 weeks. Although no rescue treatments were allowed in participants on study treatment protocol, as a safety precaution, participants could drop out of study treatment and initiate standard of care (anti-VEGF).

STAIRWAY was a patient- and outcome assessor (BCVA and central reading center)–masked trial that allowed for a single investigator per site while fulfilling masking requirements. Study participants and BCVA examiners were masked to treatment assignment. The investigator administering the patient's treatment and/or designated personnel responsible for study drug preparation was unmasked to treatment assignment. Central reading center personnel, study vendors, and the sponsor and its agents were masked to study eye drug assignment.

Outcomes

The primary efficacy outcome measure was mean change from baseline BCVA at week 40. Key secondary visual acuity outcome measures were mean change from baseline BCVA evaluated monthly over time and proportion of participants gaining or not losing at least 15, at least 10, at least 5, or at least 0 ETDRS letters from baseline over time. Key secondary anatomic outcome measures were mean change from baseline in CST over time using SD-OCT and mean change from baseline in total lesion area and area of total lesion leakage at weeks 40 and 52 using FA.

Exploratory outcome measures included proportion of participants with disease activity at week 24. Safety outcome measures included incidence and severity of ocular and nonocular adverse events (AEs).

Statistical Analysis

Primary, secondary, and exploratory efficacy analyses were performed for all randomized participants, except for 5 participants excluded from all analyses owing to GCP noncompliance at a single site. The safety analysis population included all randomized participants (excluding 5 participants from the GCP noncompliance site) who received at least 1 dose of study treatment, whether prematurely withdrawn from the study or not.

Study sample size was determined assuming a common SD for BCVA change from baseline of 13.5 ETDRS letters, where distance from the difference of the means between faricimab and ranibizumab to the 2-sided 80% CI bounds was estimated to be 5.5 letters.

The primary efficacy analysis of BCVA change from baseline at week 40 was performed using a mixed model for repeated measurements, including the categorical covariates of treatment group, visit, and visit-by-treatment group interaction and the continuous covariate of baseline BCVA. An unstructured covariance was used to account for within-patient correlation. Formal statistical comparisons were not performed across treatment arms for any efficacy end point. There was no formal type I error correction for multiple testing.

Secondary efficacy analysis of BCVA change from baseline over time was performed using a mixed model for repeated measurements as described earlier. Categorical outcomes measured repeatedly were based on observed data. Exploratory efficacy analysis of proportion of patients with disease activity at week 24 was reported with the corresponding 80% CIs by study arm. Data acquisition and data processing of the controls and samples were performed by Gen5 Secure Software, version 1.08 or higher. Analysis began January 2017 and ended March 2018.

Results

STAIRWAY Enrollment and Patient Disposition

STAIRWAY enrolled 76 anti-VEGF treatment-naive patients with nAMD (**Figure 1** and eFigure 1 in Supplement 2). Enrolled participants received ranibizumab, 0.5 mg, every 4 weeks (16 [20.2%]); faricimab, 6.0 mg, every 12 weeks (29 [36.7%]); and faricimab, 6.0 mg, every 16 weeks (31 [39.2%]). Good Clinical Practice violations of data falsification at a single site were identified during routine monitoring, followed up by an audit, and reported to the institutional review board and US Food and Drug Administration. The 5 participants from this site were excluded from efficacy and safety analyses (including the safety-evaluable population) and did not demonstrate additional BCVA benefit or new safety signals compared with ranibizumab, 0.5 mg, every 4 weeks. Of 71 participants, 64 (90.1%) attended the primary end point week-40 visit, and 65 (91.5%) completed the study through week 52. Patient discontinuation was relatively balanced across the faricimab arms (Figure 1). Overall, the reasons from discontinuation were: (1) noncompliance with study visits (1 [1.4%]), (2) death (3 [4.2%]), (3) principal investigator (A.M.K.) wanted to treat with standard of care instead (1 [1.4%]), and (4) disease activity detected (1 [1.4%]).

At least 1 major protocol deviation was reported for 7 participants (9.9%). All protocol deviations were considered to be procedural and had no meaningful effect on the safety and efficacy findings.

Baseline Characteristics

Baseline patient demographics and ocular characteristics in STAIRWAY were generally balanced across treatment arms

Figure 1. CONSORT Flow Diagram of the STAIRWAY Study



Patients were randomized 1:2:2 into the ranibizumab, 0.5 mg, every 4 weeks; faricimab, 6.0 mg, every 12 weeks; and faricimab, 6.0 mg, every 16 weeks treatment arms. Only 1 eye was chosen as the study eye.

[a] Five participants were removed from the analysis due to Good Clinical Practice (GCP) violations at a single site.

Table 1. Baseline Patient Demographics and Ocular Characteristics

Characteristic	Ranibizumab, 0.5 mg, every 4 wk (n = 16)	Faricimab, 6.0 mg, every 12 wk (n = 24)	Faricimab, 6.0 mg, every 16 wk (n = 31)	All participants (N = 71)
Age, mean (SD), y	77.3 (10.29)	80.3 (7.23)	77.7 (8.38)	78.5 (8.47)
Female, No. (%)	10 (62.5)	13 (54.2)	18 (58.1)	41 (57.7)
Race, No. (%)				
Asian	0	0	1 (3.2)	1 (1.4)
Black or African American	0	1 (4.2)	0	1 (1.4)
White	16 (100.0)	23 (95.8)	30 (96.8)	69 (97.2)
BCVA, mean (SD), ETDRS letters	55.3 (12.1)	57.8 (10.5)	60.4 (10.8)	58.4 (11.0)
CST, mean (SD), µm	443.1 (125.0)	417.9 (84.3)	382.2 (80.9)	408.0 (95.4)
CNV lesion type, No. (%)				
Classic and occult	6 (37.5)	9 (37.5)	9 (29.0)	24 (33.8)
Classic	2 (12.5)	0	2 (6.5)	4 (5.6)
Occult	8 (50.0)	15 (62.5)	20 (64.5)	43 (60.6)
Total lesion area, mean (SD), mm^2	7.3 (2.9)	7.1 (3.9)	5.9 (3.8)	6.6 (3.6)
Area of total lesion leakage, mean (SD), mm^2	7.6 (2.9)	7.1 (3.8)	6.1 (3.4)	6.7 (3.5)

Abbreviations: BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study.

(**Table 1**). The mean (SD) age for all participants was 78.5 (8.5) years (range, 56-94 years), and 41 participants (58%) were female. Small differences in baseline BCVA and CST across arms were observed owing to the relatively small sample size. Mean baseline BCVA ETDRS letter scores were 55.3 (approximate Snellen equivalent, 20/80), 57.8 (approximate Snellen equivalent, 20/63), and 60.4 (approximate Snellen equivalent, 20/63), respectively, in the ranibizumab arm with dosing every 4 weeks, faricimab arm with dosing every 12 weeks, and faricimab arm with dosing every 16 weeks; mean (SD) baseline CST as measured by SD-OCT was 443.1 (125.0) µm, 417.9 (84.3) µm, and 382.2 (80.9) µm, in the ranibizumab arm with dosing every 4 weeks, faricimab arm with dosing every 12 weeks, and faricimab arm with dosing every 16 weeks, respectively. The mean (SD) total lesion area as measured by FA was 7.3 (2.9) mm^2, 7.1 (3.9) mm^2, and 5.9 (3.8) mm^2, and the mean (SD) area of total lesion leakage was 7.6 (2.9) mm^2, 7.1 (3.8) mm^2, and 6.1 (3.4) mm^2, in the ranibizumab arm with dosing every 4 weeks, faricimab arm with dosing every 12 weeks, and faricimab arm with dosing every 16 weeks, respectively.

Efficacy Outcomes

Disease Activity Assessment

Disease activity in STAIRWAY was assessed using the per-protocol defined criteria shown in eFigure 2 and eTable 2 in Supplement 2. At week 24, 12 weeks after the last loading dose, 65% (36 of 55) of all faricimab-treated participants had no disease activity. In the faricimab arm with dosing every 16 weeks, 61% (19 of 31) of participants had no disease activity at week 24 and were qualified to continue receiving a dosing regimen every 16 weeks through study end (with the exception of 1 patient who discontinued prior to week 24). In the faricimab arm

Figure 2. Key Vision Outcome: BCVA Change From Baseline Over Time



Sample size, No.														
Ranibizumab, 0.5 mg, every 4 wk	16	16	15	16	16	16	16	16	16	16	15	16	16	16
Faricimab, 6.0 mg, every 12 wk	24	24	24	23	23	23	23	23	23	22	21	20	21	21
Faricimab, 6.0 mg, every 16 wk	31	31	30	30	30	30	30	30	30	29	28	29	28	28

Least squares means from linear model analysis of study eye best-corrected visual acuity (BCVA) change from baseline. Model includes categorical covariates of treatment group, visit, visit-by-treatment group interaction, and the continuous covariate of baseline BCVA. For those taking ranibizumab, 0.5 mg, every 4 weeks, there was a mean change of 9.6 Early Treatment Diabetic Retinopathy Study (ETDRS) letters after a mean of 12.9 injections to week 52. For those taking faricimab, 6.0 mg, every 12 weeks, there was a mean change of 10.1 ETDRS letters after a mean of 6.7 injections to week 52. For those taking faricimab, 6.0 mg, every 16 weeks, there was a mean change of 11.4 ETDRS letters after a mean of 6.2 injections to week 52. Error bars represent 80% CIs.

with dosing every 12 weeks, 71% (17 of 24) of participants showed no signs of disease activity at week 24. Ninety-four percent (15 of 16) of participants in the ranibizumab arm with dosing every 4 weeks had no disease activity at week 24, 4 weeks after the last ranibizumab dose.

Participants randomized to the faricimab arms with dosing every 16 weeks and with dosing every 12 weeks achieved visual acuity gains comparable with participants randomized to the ranibizumab arm with dosing every 4 weeks but with fewer injections. Including the initial 4 monthly initiation injections for faricimab participants, participants received a mean (SD) of 12.9 (0.25), 6.7 (0.91), and 6.2 (0.93) total injections in the ranibizumab arm of dosing every 4 weeks, faricimab arm of dosing every 12 weeks, and faricimab arm of dosing every 16 weeks, respectively, over 52 weeks. No additional injections were allowed other than the assigned dosing intervals in the faricimab arm of dosing every 16 weeks or arm of dosing every 12 weeks.

Visual Acuity Outcomes

At the primary end point of week 40, faricimab treatment with dosing every 16 weeks and dosing every 12 weeks resulted in vision gains comparable with ranibizumab fixed dosing every 4 weeks (**Figure 2** and eTable 3 in Supplement 2).

The proportion of participants gaining at least 15 ETDRS letters from baseline and proportion not losing at least 15 ETDRS letters from baseline at weeks 40 and 52 are provided in eTable 3 in Supplement 2. The proportion of participants gaining or not losing at least 10, at least 5, and at least 0 ETDRS letters from baseline at weeks 40 and 52 are provided in eTable 4 in Supplement 2.

Anatomic Outcomes

Anatomic outcomes as assessed by SD-OCT and FA at weeks 40 and 52 support the visual acuity outcomes in STAIRWAY (eTable 3 in Supplement 2). Treatment with faricimab dosing every 16 weeks and faricimab dosing every 12 weeks resulted in CST reductions and changes in total lesion area comparable with ranibizumab treatment (**Figure 3** and eTable 3 and eFigure 3 in Supplement 2).

Safety Outcomes

The safety analysis population included all randomized participants (excluding 5 participants from a single site owing to GCP noncompliance) who received at least 1 dose of study treatment, withdrawn from the study or not. Key ocular and nonocular safety events are shown in **Table 2**. Of 71 participants, 54 (76.1%) experienced at least 1 AE (ranibizumab every 4 weeks, 81.3% [13 of 16]; faricimab every 12 weeks, 75.0% [18 of 24]; faricimab dosing every 16 weeks, 74.2% [23 of 31]). Overall, 39.4% (28 of 71) of participants experienced an ocular AE in the study eye (Table 2). There were no serious ocular AEs in the study or fellow eyes. Sixty-one percent (43 of 71) of participants experienced at least 1 nonocular AE (Table 2), but none were considered related to study treatment. No AEs were reported that led to discontinuation of treatment. Three participants experienced AEs with a fatal outcome, due to either ischemic stroke (faricimab every 12 weeks), sepsis (faricimab dosing every 16 weeks), or metastatic neoplasm (faricimab dosing every 16 weeks); none were considered related to study treatment per the study investigator's assessment. Full listings of ocular and nonocular safety events are provided in eTables 5, 6, and 7 in Supplement 2. Overall, faricimab was well

Figure 3. Key Anatomic Outcomes



Sample size, No.														
Ranibizumab, 0.5 mg, every 4 wk	16	16	15	16	16	16	16	16	16	16	15	16	16	16
Faricimab, 6.0 mg, every 12 wk	24	24	24	22	23	23	23	23	23	22	21	20	21	21
Faricimab, 6.0 mg, every 16 wk	31	31	30	30	30	30	30	30	30	29	27	29	28	28

Central subfield thickness (CST) reduction from baseline over time. Least squares means from linear model analysis of study eye CST change from baseline. Model includes categorical covariates of treatment group, visit, visit-by-treatment group interaction, and the continuous covariate of baseline CST. For those taking ranibizumab, 0.5 mg, every 4 weeks, there was a mean change of −129.9 µm. For those taking faricimab, 6.0 mg, every 12 weeks, there was a mean change of −138.5 µm. For those taking faricimab, 6.0 mg, every 16 weeks, there was a mean change of −122.5 µm. Error bars represent 80% CIs.

Table 2. Key Ocular and Nonocular AEs

Selected AEs[a]	No. (%)		
	Ranibizumab, 0.5 mg, every 4 wk (n = 16)	Faricimab, 6.0 mg, every 12 wk (n = 24)	Faricimab, 6.0 mg, every 16 wk (n = 31)
Ocular AE (study eye)	8 (50.0)	9 (37.5)	11 (35.5)
Serious ocular AE (study eye)	0	0	0
Nonocular AE	9 (56.3)	14 (58.3)	20 (64.5)
Serious nonocular AE	0	4 (16.7)[b]	3 (9.7)[c]
Intraocular inflammation[d]	0	1 (4.2)	1 (3.2)
Endophthalmitis	0	0	0
Retinal detachment	0	0	0
Vitreous hemorrhage	0	0	1 (3.2)
Hypertension	1 (6.3)	0	1 (3.2)
APTC events			
Nonfatal myocardial infarction	0	0	0
Nonfatal stroke	0	1 (4.2)	0
Vascular or cardiac death or death or unknown cause	0	1 (4.2)[e]	0
Combined APTC events	0	2 (8.3)	0
Any other death	0	0	2 (6.5)[f]
IOP increased	1 (6.3)	0	0

Abbreviations: AE, adverse event; APTC, Anti-Platelet Trialists' Collaboration; IOP, intraocular pressure.

[a] Study eye or nonocular; total participants with ≥1 AE. Multiple occurrences of the same event in 1 individual counted only once.

[b] Seven events in 4 patients: acute left ventricular failure, coronary artery disease, fall, headache, ischemic stroke, mental status changes, and vertigo.

[c] Three events in 3 patients: atrial fibrillation, metastatic neoplasm, and sepsis.

[d] Defined as all AEs that are potentially indicative of intraocular inflammation as reported by the investigator, including flares and cells in the anterior chamber of any severity; 1 case of mild iritis and 1 case of mild anterior chamber flare.

[e] Ischemic stroke.

[f] Sepsis, metastatic neoplasm.

tolerated, and there were no new or unexpected safety events observed in STAIRWAY.

Discussion

In the STAIRWAY phase 2 study of faricimab for nAMD, initial vision gains were maintained with faricimab dosing every 16 weeks and dosing every 12 weeks over 52 weeks. No clinically important differences between the faricimab and ranibizumab treatment arms were identified. The results with faricimab support further exploration in the phase 3 trials. There were no new or unexpected safety events in STAIRWAY, comparable with the overall safety profile across the faricimab phase 1 and phase 2 studies (AVENUE, STAIRWAY, and BOULEVARD) that enrolled nearly 600 patients.[16,20,23] Simultaneous neutralization of Ang-2 and VEGF-A with faricimab may allow for fewer injections, addressing the high unmet need for more sustained treatments in the real world (**Video**).

The sustained efficacy potential of faricimab with dosing every 16 weeks, as shown in STAIRWAY, has not been demonstrated in any of the previous nAMD studies with anti-VEGF monotherapy injections. Extending to dosing every 16 weeks as shown in STAIRWAY has never been tried in previous nAMD trials, to our knowledge. This study did not intend to directly compare performance of faricimab with ranibizumab dosage using treat-and-extend regimen because this is not a dosing regimen accepted by the US Food and Drug Administration for use of ranibizumab in nAMD. Although there have been multiple clinical trials, for example, PIER, EXCITE, and VIEW (VIEW 1 and VIEW 2), that have studied less frequent than monthly dosing with ranibizumab, BCVA outcomes have not been shown to be equivalent to those reported with monthly dosing. Therefore, to maximize visual acuity gains with ranibizumab, the US Food and Drug Administration recommends monthly dosing. The heterogeneity of anti-VEGF response in the nAMD population poses a challenge for implementing such low-frequency regimens in studies, which has previously been associated with mean loss of vision from baseline. For example, the clinical trials PIER, EXCITE, and VIEW (VIEW 1 and VIEW 2) investigated dosing every 12 weeks with anti-VEGF agents, without the possibility of rescue injections, and showed a decline in BCVA gains, on average, across their nAMD study populations.[24-26] Even with careful monitoring, only approximately half of patients with nAMD can be extended to dosing every 12 weeks with anti-VEGF monotherapy injections, including with the next-generation anti-VEGF agent brolucizumab.[27]

The prespecified dosing regimen of every 16 weeks, where participants had the opportunity to receive dosing every 12 weeks based on their early response to faricimab treatment at week 24, compensated for the lack of predictive injection frequency biomarkers in the heterogeneous nAMD population. Week 24 was 12 weeks since the last injection for all faricimab participants and only 4 weeks since the last injection for ranibizumab participants. While overall BCVA and CST values were comparable across the faricimab dosing arm of every 12 weeks and dosing arm of every 16 weeks and the ranibizumab dosing arm of every 4 weeks at week 24, higher disease activity rates were detected in the faricimab dosing every 12 weeks and dosing every 16 weeks arms compared with the ranibizumab dosing every 4 weeks arm. This discrepancy in disease activity rates at week 24 did not result in overall major BCVA or CST change, on average, as shown by no detectable difference among treatment arms on BCVA and CST. In addition to CST change, the disease activity criteria also included BCVA loss due to nAMD activity, presence of hemorrhage, and investigator opinion. Therefore, in a proportion of cases, qualitative changes on OCT may have contributed to investigator determination of active disease. These results indicate a lack of correlation between OCT changes and BCVA outcomes in the nAMD population and also support the ongoing debate regarding the importance of subretinal fluid, OCT fluctuation, and drying on vision maintenance.[28,29]

Limitations

A limitation of STAIRWAY was the relatively small sample size. As a phase 2 study with 71 participants analyzed, the typical post hoc analyses of patient subgroups would be challenging to interpret. Formal statistical comparisons were not performed across the treatment arms. Also, the vascular stability effect of Ang-2 neutralization may require a longer study, and OCT and FA alone may not be sufficient to assess the full effect of Ang-2 neutralization. Additionally, more advanced imaging methodologies may be able to provide improved understanding of the faricimab mechanism of action.

Conclusions

In conclusion, the faricimab dosing regimen every 16 weeks resulted in maintenance of initial vision and anatomic improvements throughout 52 weeks that were comparable with outcomes achieved with monthly ranibizumab injections, extending results of the larger AVENUE phase 2 trial.[16] The phase 3, identically designed, randomized, controlled, statistically powered clinical trials TENAYA (NCT03823287) and LUCERNE (NCT03823300) are currently underway and will validate whether STAIRWAY durability outcomes are reproducible across a larger population. By demonstrating comparable outcomes with anti-VEGF monotherapy with fewer injections in STAIRWAY, faricimab demonstrated its potential to provide sustained efficacy through extended durability and reduce treatment burden.

ARTICLE INFORMATION

Accepted for Publication: March 27, 2020.

Published Online: July 30, 2020. doi:10.1001/jamaophthalmol.2020.2699

Author Affiliations: Sierra Eye Associates, Reno, Nevada (Khanani); Reno School of Medicine, University of Nevada, Reno (Khanani); West Texas Retina Consultants, Abilene (Patel); Long Island and Queens Vitreoretinal Consultants, PC, Great Neck, New York (Ferrone); Genentech Inc, South San Francisco, California (Osborne, Grzeschik, Basu, Ehrlich, Haskova); now with Adverum Biotechnologies Inc, Menlo Park, California (Osborne); Roche Innovation Center Basel, Roche Pharma Research and Early Development, F. Hoffmann-La Roche, Basel, Switzerland (Sahni); now with Roche Products (Ireland), Dublin, Ireland (Basu); now with Kodiak Sciences Inc, Palo Alto, California (Ehrlich); Retinal Consultants of Arizona, Phoenix (Dugel); USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles (Dugel); now with IVERIC bio, New York, New York (Dugel).

Author Contributions: Drs Khanani and Basu had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Khanani, Patel, Osborne, Sahni, Grzeschik, Ehrlich, Haskova, Dugel.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Patel, Osborne, Sahni, Grzeschik, Basu, Haskova, Dugel.
Critical revision of the manuscript for important intellectual content: Khanani, Patel, Ferrone, Osborne, Sahni, Ehrlich, Haskova, Dugel.
Statistical analysis: Grzeschik, Basu, Dugel.
Obtained funding: Osborne, Sahni, Ehrlich.
Administrative, technical, or material support: Khanani, Osborne, Grzeschik, Ehrlich, Haskova.
Supervision: Patel, Ferrone, Osborne, Sahni, Ehrlich, Haskova, Dugel.

Conflict of Interest Disclosures: Dr Khanani reported grants from Adverum Biotechnologies, Allergan, Chengdu Kanghong, Genentech Inc, Graybug, Gyroscope, Gemini Therapeutics, Kodiak, Novartis, Iveric Bio, Opthea, Oxurion, Recens Medical, Regenxbio, and Roche during the conduct of the study and is a consultant for Adverum Biotechnologies, Allergan, Bausch and Lomb, Chengdu Kanghong, DORC, Eyepoint Pharmaceuticals, Gemini Therapeutics, Genentech Inc, Graybug, Gyroscope, Kodiak Sciences, Novartis, Opthea, Oxurion, Recens Medical, and Regenxbio; and reports speaker fees from Allergan and Novartis. Dr Patel reported grants and personal fees from Genentech Inc/Roche during the conduct of the study; grants and personal fees from Allergan and grants and personal fees from Kodiak Sciences outside the submitted work; and grants from Aerie Pharmaceuticals, Apellis Pharmaceuticals, Boehringer Ingelheim, Chengdu Kanghong, Clearside, Ionis Pharmaceuticals, Mylan, Novartis, Opthea, Ophthotech, OraPharma, Regeneron, Samsung, Stealth BioTherapeutics, Xbrane Biopharma, and ThromboGenics outside the submitted work. Dr Ferrone reported grants from Genentech Inc during the conduct of the study and other support from Genentech Inc outside the submitted work. Dr Osborne reported a patent to faricimab dosing regimen pending and is an employee of and holds stock options in Adverum Biotechnologies. Dr Sahni reported other support from F. Hoffmann-La Roche during the conduct of the study and outside the submitted work and is also an employee and shareholder at F. Hoffmann-La Roche. Dr Basu reported personal fees from Genentech Inc during the conduct of the study and is an employee of Roche Products (Ireland). Dr Ehrlich reported personal fees and other support from Genentech Inc and Kodiak Sciences outside the submitted work. Dr Haskova is an employee of Genentech Inc and reported other support from Genentech Inc during the conduct of the study and outside the submitted work. No other disclosures were reported.

Funding/Support: F. Hoffmann-La Roche provided financial support for the study.

Role of the Funder/Sponsor: F. Hoffmann-La Roche participated in the study design; conducting the study; data collection, management, analysis, and interpretation; and preparation, review, and approval of the manuscript.

Meeting Presentation: Portions of these data were presented at the Retina Society 51st Scientific Program; September 13, 2018; San Francisco, California; American Academy of Ophthalmology Retina Subspecialty Day; October 26, 2018; Chicago, Illinois; 12th Asia-Pacific Vitreo-retina Society Congress; December 14, 2018; Seoul, South Korea; Asia-Pacific Academy of Ophthalmology Congress; March 9, 2019; Bangkok, Thailand; Retina World Congress; March 22, 2019; Fort Lauderdale, Florida; 123rd Annual Meeting of the Japanese Ophthalmological Society; April 19, 2019; Tokyo, Japan; Association for Research in Vision and Ophthalmology Annual Meeting; April 28, 2019; Vancouver, Canada; 34th Pan-American Congress of Ophthalmology; May 26, 2019; Cancun, Mexico; American Society of Retina Specialists 37th Annual Meeting; July 27, 2019; Chicago, Illinois; 19th EURETINA Congress; September 7, 2019; Paris, France; and Retina Society 52nd Scientific Program; September 12, 2019; London, United Kingdom.

Data Sharing Statement: See Supplement 3.

Additional Contributions: We thank Dietmar Schwab, PhD (F. Hoffmann-La Roche), and Robert Weikert, MSc (F. Hoffmann-La Roche), for their contributions to the STAIRWAY study in their capacity as clinical scientists; neither were compensated beyond their standard salary. Third-party writing assistance (manuscript draft preparation and revision per author direction) was provided by Charlotte A. Osborne, PhD, CMPP (Envision Pharma Group), and Priyanka Narang, PhD (Envision Pharma Group), and funded by F. Hoffmann-La Roche.

REFERENCES

1. Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. *Nat Rev Drug Discov*. 2016;15(6):385-403. doi:10.1038/nrd.2015.17

2. American Academy of Ophthalmology. Age-related macular degeneration PPP 2019. Published October 2019. Accessed January 15, 2020. https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp

3. Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. *J Manag Care Spec Pharm*. 2018;24(2-a suppl):S3-S15. doi:10.18553/jmcp.2018.24.2-a.s3

4. Ozturk M, Harris ML, Nguyen V, Barthelmes D, Gillies MC, Mehta H. Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence. *Clin Exp Ophthalmol*. 2018;46(4):407-411. doi:10.1111/ceo.13085

5. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. *Ophthalmology*. 2014;121(5):1092-1101. doi:10.1016/j.ophtha.2013.11.031

6. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. *Br J Ophthalmol*. 2015;99(2):220-226. doi:10.1136/bjophthalmol-2014-305327

7. Cohen SY, Mimoun G, Oubraham H, et al; LUMIERE Study Group. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. *Retina*. 2013;33(3):474-481. doi:10.1097/IAE.0b013e31827b6324

8. Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study: a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. *Acta Ophthalmol*. 2013;91(6):540-546. doi:10.1111/j.1755-3768.2012.02493.x

9. Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC. Real-world outcomes of anti–vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. *Ophthalmol Retina*. 2018;2(7):645-653. doi:10.1016/j.oret.2018.01.006

10. Gohil R, Crosby-Nwaobi R, Forbes A, Burton B, Hykin P, Sivaprasad S. Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration. *PLoS One*. 2015;10(6):e0129361. doi:10.1371/journal.pone.0129361

11. Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. *Am J Ophthalmol*. 2015;160(4):725-31.e1. doi:10.1016/j.ajo.2015.06.023

12. Varano M, Eter N, Winyard S, Wittrup-Jensen KU, Navarro R, Heraghty J. Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey. *Clin Ophthalmol*. 2015;9:2243-2250. doi:10.2147/OPTH.S92548

13. Vukicevic M, Heraghty J, Cummins R, Gopinath B, Mitchell P. Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration. *Eye (Lond)*. 2016;30(3):413-421. doi:10.1038/eye.2015.235

14. Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. *EMBO Mol Med*. 2016;8(11):1265-1288. doi:10.15252/emmm.201505889

15. Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. *EMBO Mol Med*. 2019;11(5):e10666. doi:10.15252/emmm.201910666

16. Sahni J, Dugel PU, Patel SS, et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. *JAMA Ophthalmol*. Published online July 30, 2020. doi:10.1001/jamaophthalmol.2020.2685

17. Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin-TIE pathway. *Nat Rev Drug Discov*. 2017;16(9):635-661. doi:10.1038/nrd.2016.278

18. Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. *Prog Retin Eye Res*. 2015;49:67-81. doi:10.1016/j.preteyeres.2015.06.002

19. Foxton RH, Uhles S, Grüner S, Revelant F, Ullmer C. Efficacy of simultaneous VEGF-A/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization. *EMBO Mol Med*. 2019;11(5):e10204. doi:10.15252/emmm.201810204

20. Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. *Ophthalmology*. 2019;126(8):1155-1170. doi:10.1016/j.ophtha.2019.03.023

21. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053.

22. US Food and Drug Administration. Regulations: good clinical practice and clinical trials. Accessed June 26, 2020. https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/regulations-good-clinical-practice-and-clinical-trials

23. Chakravarthy U, Bailey C, Brown D, et al. Phase I trial of anti-vascular endothelial growth factor/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration. *Ophthalmol Retina*. 2017;1(6):474-485. doi:10.1016/j.oret.2017.03.003

24. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. *Am J Ophthalmol*. 2010;150(3):315-324.e1. doi:10.1016/j.ajo.2010.04.011

25. Schmidt-Erfurth U, Eldem B, Guymer R, et al; EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. *Ophthalmology*. 2011;118(5):831-839. doi:10.1016/j.ophtha.2010.09.004

26. Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. *Ophthalmology*. 2014;121(1):193-201. doi:10.1016/j.ophtha.2013.08.011

27. Dugel PU, Koh A, Ogura Y, et al; HAWK and HARRIER Study Investigators. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. *Ophthalmology*. 2020;127(1):72-84. doi:10.1016/j.ophtha.2019.04.017

28. Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration: a phase IV randomised clinical trial with ranibizumab: the FLUID study. *BMC Ophthalmol*. 2016;16:31. doi:10.1186/s12886-016-0207-3

29. Sharma S, Toth CA, Daniel E, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. *Ophthalmology*. 2016;123(4):865-875. doi:10.1016/j.ophtha.2015.12.002